Anup Marda
Fortune : 96 000 $ au 30/09/2026
Fortune : 96 000 $ au 30/09/2026
Anup Marda is currently Chief Financial & Accounting Officer at Cabaletta Bio, Inc. since 2019.
Formerly, Mr. Marda was Executive Director at US Pharmaceuticals, Inc. from 2012 to 2014 and VP, Head-Global Financial Planning & Analysis at Bristol Myers Squibb Co. from 2018 to 2019.
Education includes an undergraduate degree from Indian Institute of Technology Bombay and an MBA from Krannert School of Management.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CABALETTA BIO, INC. 0,03 % | 02/03/2026 | 50 000 ( 0,03 % ) | 96 000 $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| CABALETTA BIO, INC. | Directeur Financier/CFO | 01/01/2019 |
| Sociétés | Poste | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2019 |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Directeur/Membre du Conseil | 01/01/2014 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Health Technology |
Indian Institute of Technology Bombay
Indian Institute of Technology Bombay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Krannert School of Management
Krannert School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which discovers and develops engineered cell therapies for B cell-mediated autoimmune diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national